Next Milestone Ventures

ParksideScientific Inc.-logo

Technologies

Therapeutic

Website

gust.com

Parkside Scientific

New York City based Parkside Scientific develops novel “best-in-class” small molecule drugs that target bromodomain (BrD) proteins for epigenetic control of gene transcription in cancers and inflammatory disorders.

Parkside Scientific Team:
Gary Duberstein

Contact
Next Milestone

Newsletter Signup

"*" indicates required fields

Name
This field is for validation purposes and should be left unchanged.

For more information about the program, please contact Program Manager, Mary Howard at Mary@FirstXFounder.com

 

Next Milestone is a Program of